Cargando…
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
BACKGROUND: The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major clinical side effect is cardiotoxicity but the mechanism is largely unknown. On...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243239/ https://www.ncbi.nlm.nih.gov/pubmed/28101782 http://dx.doi.org/10.1186/s40169-016-0133-2 |